<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42713">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550288</url>
  </required_header>
  <id_info>
    <org_study_id>0653C-383</org_study_id>
    <secondary_id>153060</secondary_id>
    <nct_id>NCT02550288</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)</brief_title>
  <official_title>A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe [EZ] 10
      mg/Atorvastatin [Atora] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg
      alone when administered to Japanese participants with hypercholesterolemia. The primary
      hypothesis is that MK-0653C (EZ 10 mg/Atorva 10 mg) is superior to EZ 10 mg and is superior
      to Atorva 10 mg and that MK-0653C (EZ 10 mg/Atorva 20 mg) is superior to EZ 10 mg and is
      superior to Atorva 20 mg in percent change from baseline in low-density lipoprotein
      cholesterol (LDL-C) after 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)</measure>
    <time_frame>up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Gallbladder-related AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Hepatitis-related AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 times Upper Normal Limit (ULN)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Potential Hy's Law Condition</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in CK ≥10xULN with Muscle Symptomss</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg +Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10 mg</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg +Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10 mg</intervention_name>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg +Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ezetimibe 10 mg tablet</intervention_name>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Atorvastatin 10 mg capsule</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet control/Daily Exercise</intervention_name>
    <description>Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg +Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese outpatient with hypercholesterolemia.

          -  Females must be non-reproductive potential or agree to remain abstinent or use (or
             partner use) two acceptable methods of birth control from date of signed informed
             consent to the 14 days after the last dose of study drug

          -  Agree to maintain a stable diet that is consistent with the Japan Atherosclerosis
             Society Guideline 2012 (JAS2012) for prevention of atherosclerotic cardiovascular
             diseases for the duration of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Type 1 or uncontrolled type 2 diabetes mellitus (treated or untreated)

          -  History of coronary artery disease (CAD) Homozygous familial hypercholesterolemia or
             has undergone LDL apheresis

          -  Had a gastrointestinal tract bypass, or other significant intestinal malabsorption

          -  History of cancer within the past 5 years except for successfully treated
             dermatological basal cell or squamous cell carcinoma or in situ cervical cancer

          -  Human immunodeficiency virus (HIV) positive

          -  History of drug/ alcohol abuse within the past 5 years or psychiatric illness not
             adequately controlled and stable on pharmacotherapy

          -  Consumes more than 25 g of alcohol per day

          -  Consumes more than 1L of grapefruit juice per day

          -  Currently following an excessive weight reduction diet

          -  Engaging in a vigorous exercise regimen (e.g.; marathon training, body building
             training etc.) or intends to start training during the study

          -  Hypersensitivity or intolerance to ezetimibe or atorvastatin

          -  History of myopathy or rhabdomyolysis with ezetimibe or any statin

          -  Pregnant or lactating

          -  Taking any other investigational drugs and/or has taken any investigational drugs
             within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 7, 2016</lastchanged_date>
  <firstreceived_date>September 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
